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ABSTRACT 
The enzyme porphobilinogen synthase (PBGS) catalyzes the conversion of two 
molecules of o-aminolevulinic acid (ALA) into porphobilinogen (PBG) in the first 
common step of the tetrapyrrole biosynthesis pathway. '0 A homology model of the R. 
sphaeroides PBGS was created by Dr. Eileen K. Jaffe at Fox Chase Cancer Center based 
on comparison to the crystal structure ofPseudomonas aeruginosa. The proposed 
structure suggests that there are four cysteines in close proximity to the active site. Three 
ofthese cysteines are not present in the highly similar R. capsulatus sequence.' Under 
oxidizing conditions these residues can potentially participate in the formation of 
disulfide bonds, which would be potential targets for reducing agents, such as p­
mercaptoethanol. This is supported by the fact that a number of PBGS enzymes require 
the addition of p-mercaptoethanol for full activity, including the Rhodobacter 
sphaeroides enzyme. To test if the three cysteines that are present in the R. sphaeroides 
enzyme, and not that of R. capsulatus, ar r sponsible for the dependence of R. 
sphaeroides on a reducing agent (p-mercaptoethanol), site-directed mutagenesis was 
performed on R. sphaeroides. After the presence of the mutations was confirmed through 
sequencing, the altered enzymes were isolated and tested for p-mercaptoethanol 
sensitivity. A decrease in sensitivity is found in all three mutants when compared to wild 
type. In two mutants of these mutan . C10 Dan C265V, the difference is very 
pronounced. A larger goal was to test whether the current structural model is sufficient to 
serve as a guide for further work on the structure-function relationships in the R. 
sphaeroides PBGS. Our results indicate that the system is more complicated than 
anticipated. Further study is needed to clarify the role of cysteine residues. 
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INTRODUCTION AND THEORY 
PBG Background 
Porphobilinogen (PBG), illustrated in Scheme 16, the monopyrrole product ofthe 
reaction catalyzed by PBGS, is a precursor to all biological tetrapyrroles. 11 Tetrapyrroles 
are four-membered heteronuclear rings that include some ofthe most widely present and 
important compounds in nature. All chlorophylls and hemes, vitamin BI2, and Factor 430 
are among the most notable compounds that are tetrapyrroles (Figure 2). II Thus 
production of PBG, which is the first common step in the biosynthesis of all tetrapyrrole 
products, is integral to sustainting life. Understanding asymmetric condensation of two 
molecules of o-aminolevulinic acid (ALA) to give one molecule ofPBG will provide 
much insight into the exciting possibilities for future clinical applications such as rational 
drug design and toxicology. Since this reaction is enzyme catalyzed, it would be 
advantageous for us to understand the mechanism by which PBGS works. 
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Scheme 1. Balanced reaction catalyzed by PBGS. The conversion of two molecules of 
8-aminolevulinic acid to one molecule of porphobilinogen and two molecules of water. 
The P-site substrate molecule, and what it contributes to the porphobilinogen, is in bold. 
The A-site substrate molecule, and what it contributes to the porphobilinogen, is not in 
bold6. 
PBGS Mechanism 
The metalloenzyme, PBGS, catalyzes the biosynthesis of PBG from two molecules of 8­
aminolevulinic acid, which is thought to occur via a Knorr type pyrrole condensationlO . 
The mechanism is fairly well supported through intermediate analog studies and 
generally accepted (mechanism in Scheme 311 and intermediate analogs in Figure 63,6).3, 
6,9,10, Jl One molecule of 8-aminolevulinic acid enters the active site of the enzyme. The 
acid forms a Schiff base with an active site lysine residue at the P-Site, which is so named 
because the substrate molecule that binds to this site contributes the propanoic acid side 
chain to porphobilinogen. Then a secoIid molecule of substrate forms 
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Scheme 3. Mechanism proposed for porphobilinogen synthesis proposed by Jordan et. 
al. Both substrate molecules are bound to enzyme through Schiff bases and C-C bond is 
the first one formed 11 . 
another Schiff base with a lysine residue in the A-site part of the active site, so named 
because the substrate molecule that binds to this site contributes the acetic acid side chain 
to the porphobilinogen. The substrate molecule at the A-site then loses a proton from the 
three position and an aldol condensation occurs. This causes a nucleophilic attack by the 
3 position carbon on the A-site substrate molecule on the carbon ofthe Schiff base of the 
P-site substrate molecule. The second proton is then lost from the three carbon on the A-
site substrate molecule and a second aldol condensation occurs. The intermediate then 
detaches from the P-site. The P-site amino group then nucleophilically attacks the Schiff 
base on the A-site substrate molecule. Then another deprotonation occurs and the newly 
synthesized porphobilinogen molecule detaches from the A-site. 
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There is still some debate over this mechanism." First, there is no evidence that 
suggests that the formation of the C-C bond preceeds C-N bond formation An alternative 
mechanism in which C-N bond first is shown in Scheme 4." The only reason the C-N 
bond is not thought to form first is that this mechanism would cause electrosteric 
hinderance for the subsequent C-C bond formation. Also, there is no definitive 
experiment demonstrating that there is a Schiff Base formed at the A-site, mechanism 
shown in Scheme 5.1' The only evidence that indicates this second Schiff Base comes 
from an intermediate analog study.6 This study revealed that intermediate analog, 4,7­
dioxosebasic acid (Figure 6), was covalently reacted with two lysine residues. However, 
whether this compound is a true analog of the porphobilinogen was not determined. 
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Scheme 4. Alternate mechanism proposed for porphobilinogen synthesis. Only one of 
the substrate molecules are bound to enzyme through a Schiff base and the C-N bond is 
the first one formed II. 
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Scheme 5. Alternate mechanism proposed for porphobilinogen synthesis. Only one of 
the substrate molecules are bound to enzyme through Schiff bases and the C-C bond is 
the first one formed II. 
Active Site 
There are two classifications of PBGS enzymes (Figure 134).4 The first 
classification is variation in active site metal ion binding. The metal ion used most is 
zinc, which is always in the +2 ionization state, Figure 14.4 The use of catalytic zinc can 
be explained in two ways. First, the transition metal does not discriminate between 
different first coordinate sphere ligands or ligation geometry. Also, zinc is fairly 
ubiquitous in most environments. Mg(II) and/or potassium(I) can also occupy this role. 
Mg(II) is thought to be used less because the alkaline earth metal prefers binding oxygen 
ligands in a rigid octahedral geometry. The binding ofK(I) shows that charge is not the 
only determinant of function. The use of monovalent cations indicate further malleability 
because monovalent cations can usually accommodate more ligands. Of all know PBGS 
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sequences, there seems to be an even split between having the determinants for zinc 
binding and having the determinants for magnesium and/or potassium binding. For those 
enzymes that have a catalytic zinc, a consensus binding motif has been assembled as 
DXCXCX(YIF)X3G(HlQ)CG, where the coordination cysteines are underlined and X has 
limited variability. However, in non-zinc binding PBGS enzymes, the active site metal 
binding sequence has been formed as DXALDX(YIF) X3G(HlQ)DG. In this aspartate 
rich sequence, the underlined aspartic acid residues underlined are thought to coordinate 
the magnesium and/or potassium. 
Allosteric Site 
The second classification is based on allosteric site metal binding.4 The 
magnesium(still +2) is thought to stabilize the monomer interactions. The complexity of 
active site metals is in stark contrast to the simplicity of allosteric site metal binding. 
PBGS enzymes either has an allosteric magnesium (still +2) at this site, an example is 
shown in Figure 154, or binds nothing at all but still has a consensus sequence. Over 90% 
of all known PBGS sequences contain the determinants for the allosteric magnesium 
binding site. This consensus sequence is :RX..164DX-6s.E:XXXD. Also, a non-magnesium 
binding allosteric site consensus sequence has been outlined as )()L164D~sXXXRD. 
Clinical Significance 
The biological importance ofderivatives of the products of the reaction that 
involves condensation of two molecules of 8-aminolevulinic acid into one 
porphobilinogen molecule leads to many clinical implications for the PBGS enzyme. 
PBGS has long been known to be the target oflead poisoning in humans.s,7,13 However, 
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the absence of a mechanism has hindered progress for clinical treatments. A recent paper 
by Jaffe et. al. proposed a mechanism through which Pb(II) inhibits PBGS activity.5 
Human PBGS is a metalloenzyme that coordinates Zn(II) with cysteine residues. There 
appear to be two distinct types of zinc binding site, named ZnA and ZnB (Figure 7\ 
This study shows that both of these sites bind preferentially to Pb(II) and the ZnA site is 
responsible for slow, tight binding ofPb(II). Their data supports Pb(II) binding to a 
hybrid site which uses ligands from both the ZnA and ZnB sites, shown in Figure 8B5, 
however does not fully exclude the Pb(II) binding to only the ZnB ligands, shown in 
figure Figure 8A.5 This Pb(II) binding is proposed to be disfavored during turnover 
because of the lone pair of electrons on Pb(II) which would alter the active site 
microenvironment thereby decreasing substrate binding and the ensuing catalysis of the 
reaction. 
Designer bioselective inhibitor production is also an exciting clinical possibility. 12 
In the past, searches for antibiotics, fungicides, herbicides, etc. have been based either 
solely upon trial and error method or a novel observation. With today's molecular 
knowledge, this process can be streamlined by removing much of the randomness of the 
search. This could be done by exploiting the differences in necessary enzymatic 
activities between host and parasite. PBGS seems to be an optimal system in which to do 
this because it is nearly omnipresent in the biotic world. Theoretically, when the human 
PBGS and a given infectious organism PBGS have been sufficiently characterized, 
differences in active and allosteric sites could be utilized to determine the attributes that a 
compound should hypothetically have to selectively disrupt the infectious agent. From 
here, chemical databanks could be searched or de novo synthesis could be used to 
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fonnulate a list of possible selectively disruptive agents. Then testing for the clinical 
effectiveness and toxicity of each compound would all that remained to do. 
PRGS Structure 
Of the over 130 sequenced PBGS enzymes, there are only X-ray crystallography 
structures for four species: yeast, E. coli, Pseudomonas aeruginosa, and human. A 
homo-octameric structure is conserved (Figure 9B8), however active site ligands vary 
(Figure 104).4 Each monomer is composed an up barrel, which contains the active site 
and an N-tenninal ann (Figure 11 11). The N-tenninal ann is involved in subunit-subunit 
interactions. It is thought that the ann of one subunit "hugs" the barrel of the other 
subunit of the dimmer. These dimers then assemble, through hydrophobic interactions, in 
to the "69" confinnation (Figure 9A8). Then four dimers assemble into an octamer in the 
D4 confinnation (Figure 9B8). Since eight spatially distinct but structurally equivalent 
subunits are identified through X-ray structures, it is reasonable to assume that there are 
eight active sites per enzyme. However there is evidence that there are only four active 
sites per homo-octamer in both mammalian and E. coli PBGS.2 This supports the theory 
that PBGS has half-site reactivity. Recently, a breakthrough experiment with 
Rhodobacter capsulatus that used both size-exclusion chromatography and analytical 
ultracentrifugation indicates that this organism's PBGS enzyme can be predominantly 
found in a very active hexameric state. 1 Also, another recent study shows that a rare 
human allele for PBGS, F12L, causes an oligomeric switch where the octamer is changed 
to a hexamer which no longer bind an allosteric magnesium (Figure 122).2 This is 
thought to destabilize the nonnal, or Mg+2-stabilized hugging dimer, making it easier to 
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take on a different dimer confirmation, called detached dimer. This detached dimer can 
form a hexamer. This conversion between oligomeric states is hypothesized to be part of 
allosteric regulation ofPBGS because there is also a marked change in pH rate profile. 
The variant has optimal Km and Vmax at pH 9 in contrast to wild type, which has an 
optimal pH of7. So in vivo, the hexamer has about 12% of the activity that the wild type 
does. Thus shifts in the oligomeric state equilibrium would be predicted to alter the 
overall PBGS activity in vivo and perhaps playa role in tetrapyrrole biosynthesis 
regulation 
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OBJECTIVE 
The immediate goal of this study is to test whether the fact that the wild type R. 
sphaeroides PBGS activiy is dependent upon ~-mercaptoethanol is due to disulfide bonds 
involving the three cysteine residues in close proximity to the active site (Figure 16). 
These disulfide bonds would necessitate a reducing environment to keep from oxidizing, 
changing the structure and possibly the activity of PBGS. 
The overall goal of this study is to test whether the structural model that has been 
prepared is sufficiently accurate to serve as a guide for further experiments on structure­
function relationships in the PBGS enzyme in R. sphaeroides. Further understanding 
structure and function will facilitate creating clinical applications. Also, in respect to the 
field of PBGS study in a whole, we would like to contribute to the amassing library of 
knowledge. This will allow future work to use a comparative method and take advantage 
on natural phylogenetic variations in the enzyme to facilitate future work. 
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RESULTS AND DISCUSSION 
The cysteine residues mutated were chosen because these cysteins are present in 
R. sphaeroides PBGS and not that ofR. capsulatus, which has high sequence homology 
with the R. sphaeroides PBGS(Figure 16). The significance of their presence only in the 
R. sphaeroides enzyme is that the R. sphaeroides enzyme is stimulated by ~­
mercaptoethanol and the R. capsulatus enzyme is not. Thus, it was hypothesized that one 
of these three cysteine residues present only in the R. sphaeroides PBGS participates in a 
disulfide bond and creates the dependence of the R. sphaeroides PBGS on the reducing 
agent ~-mercaptoethanol. Also, since the justification of mutant choice was based on the 
homology between the R. sphaeroides and R. capsulatus PBGS, the residues mutated in 
the R. sphaeroides enzyme were changed to the amino acid found in the corresponding 
position in the R. capsulatus enzyme. 
Sequencing was sent to MWG Bioscience. Alignments were then made between 
each mutant nucleotide sequence and wild type nucleotide sequence (Figure 19 and 20). 
The sequencing confirmed mutants C103D and C265V, however MWG was unable to 
sequence the C309A mutant. There is evidence to support the creation ofC309A though. 
The C309A PBGS is stimulated markedly less by ~-mercaptoethanol than the wild type 
PBGS. This supports the mutation of a disulfide participating cysteine residue to a non­
disulfide participating amino acid residue. 
The PBGS activity assays were run and the change in absorbance at 555 run was 
used to determine enzymatic activity. To determine total protein concentration, Bradford 
assays were run and the change in absorbance at 595 nm was taken. Specific activity, 
which is essentially a measure of sample purity, of each assay was then calculated by 
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dividing the PBGS enzymatic activity by the total protein concentration. Then the 
specific activities of each sample in the presence and absence of ~-mercaptoethanolwere 
compared against each other(Figure 17 and 18). The specific activities of all the mutants 
were not as drastically decreased by the absence of ~-mercaptoethanolas was the wild 
type. However, the specific activity of mutant C309A was stimulated markedly more 
than either mutant C103D or mutant C265V, and thus had enzymatic activity more 
similar to that of the wild type. Also, mutant C265V has low specific activity across the 
board which indicates that this cysteine may be an important residue. 
For the purpose of this study, the simplest system that could exist would be one 
where the PBGS of R. sphaeroides has only one disulfide bond. The results that we 
would expect from this enzyme would be a total lack of stimulation by ~­
mercaptoethanol in mutant enzymes that contained amino acid changes at any cysteine 
residue that participated in the disulfide bond. In this theoretical system, at most two of 
the cysteine residues tested could participate in the disulfide bond and therefore only two 
of the tested mutants would lack any stimulation by ~-mercaptoethanol. However, this is 
not what was observed. All three mutants were stimulated to some degree but none of 
the mutations were stimulated as much as the wild type. Mutant C103D PBGS has high 
overall activity and little stimulation by ~-mercaptoethanol when compared to the wild 
type PBGS. The lack of stimulation suggests that this cysteine residue does participate in 
a disulfide bond. Also, the retention of a relatively high specific activity indicates that 
this mutated residue was not otherwise important to the function of the active site. 
Mutant C265V also had little stimulation by ~-mercaptoethanol, but this mutant enzyme 
did not retain a relatively high specific activity. The overall loss of activity suggests that 
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this cysteine residue is important to the function of the active site in addition to possibly 
participating in a disulfide bond. The last mutant, C309A, retained high specific activity, 
however it showed more considerable stimulation by ~-mercaptoethanol. With this 
evidence, it is hard to suggest that the residue does or does not participate in a disulfide 
bond. 
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FUTURE WORK
 
First and foremost, more extensive mutations of cysteine residues need to be 
made and evaluated. For safe measure, the fourth cysteine residue at position 315 in 
Figure 16, which is present in both Rhodobacter species, (Figure 16) should be mutated 
and evaluated. That work should be followed by making various combinations of 
cysteine residues to determine exactly which residues were interacting in each disulfide 
bond. 
Then reciprocal mutations should be made in R. capsulatus by changing amino 
acid residues to cysteines at corresponding positions to the mutations made in R. 
sphaeroides PBGS. These mutants should then be confirmed, purified, and tested for ~­
mercaptoethanol sensitivity. If the ree'pro mutations in R. capsulatus imparted ~­
mercaptoethanol sensitivity, then this would further confirm that cysteine residues in R. 
sphaeroides are participating in structurally and functionally important disulfide bonds. 
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METHODS AND MATERIALS 
Mutagenesis 
Mutagenesis was carried out with Stratagene QuickChange Site-Directed 
Mutagenesis Kit. This was used to create three different mutants. The first was to 
change a cysteine residue to an aspartate at amino acid position 103. This mutant will be 
referred to as CI03D. Primers were 5'-ggcctggaaccccgacaacctcgccaaccgg-3' and 5'­
ccggttggcgaggttgtcggggttccaggcc-3' where the mutated residue is in bold. The second 
mutation was the change from a cysteine to a valine at amino acid residue at 265. This 
mutant will be referred to as C265V. Primers were 5'­
ccctatctcgacatcgtccggcgggtgaaggacgc-3' and 5'-gcgtccttcacccgccggacgatgtcgagataggg­
3'. The third mutant made was a cysteine to an alanine at residue 309. This mutant will 
be referred to as C309A. Primers were 5'-ccctatctcgacatcgcccggcgggtgaaggacgc-3' and 
5'-gcgtccttcacccgccgggcgatgtcgagataggg-3' where the mutated residue is in bold. 
Plasmid Purification 
Mutant plasmid was transformed into XLI-Blue Supercompetent cells (from 
Stratagene). Then plasmid purification was carried out by QIAGEN-tip 100 Midiprep 
Kit. 
Sequencing 
Each purified plasmid (20 Ill) was sent ofto MWG Bioscience. Then alignments 
were created between the mutant sequences and the wild type sequence using NCBI Blast 
(Figures 19 and 20). 
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Mutant Protein Purification 
The mutant and wild type plasmid wase transformed into BLR Supercompetent 
cells (Novagen), plated on LB with ampicillin and tetracycline and grown overnight at 37 
DC. A single colony was then innoculated in 1 L LB with 0.4% glucose and 50mg/L of 
carbenicillin at 37 DC for 16 hours. The cells were spun down and pellets were 
resuspended for induction in 1 L of LB with 100 ~M IPTG and 50 mglL of carbenicillin 
at 15 DC for 24 hours. The cells were spun down and each pellet was resuspended in 20 
ml of Lysis buffer (0.1 M Tris, 10 mM ~-mercaptoethanol, 30 mM KCI, pH 8.5). The 
cells were then lysed using a French Press and treated with benzonuclease. Cellular 
debris was pelleted out with centrifugation at 21,500 x g and 4 DC for 15 minutes with a 
Beckman JLA-16.250 rotor. Ammonium sulfate precipitation was performed with the 
supernatant until ammonium sulfate was 25% saturation. To pellet the PBGS protein, 
centrifugation at 31,000 x g and 4 DC for 20 minutes with a Beckman JLA-16.250 rotor 
was performed. This pellet was then resuspended in 5 mL of Lysis buffer. 
Wild Type Protein Purification 
Purification of wild type protein follows all the steps included in the mutant 
protein purification but then is purified even further by three consecutive columns. After 
the ammonium sulfate precipitation pellet was resuspended in 5 ml of Lysis buffer, it was 
loaded on a HiPrep 16/1 0 Pheny FF phenyl sepharose column(Amersham-Pharmacia), 
which separates on degrees of hydrophobicity. The column was washed with Pheny Seph 
buffer A ( 30 mM Tris, 10 mM ~-mercaptoethanol, pH 7) and eluted with a gradient from 
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Pheny Seph buffer A to Pheny Seph Buffer B (0.1 M Tris, 20% ammonium sulfate, 10 
rnM ~-mercaptoethanol, pH 7). Fractions were collected and PBGS activity assays were 
run on the fractions. Fractions that showed high activity (OD of activity assay greater 
than 0.150) were pooled and loaded on a HiPrep 16/10 DEAE FF anion exchange column 
from Amersham-Pharmacia. The column was washed with DEAE buffer A (30 rnM 
Tris, 10 rnM ~-mercaptoethanol, pH 7) and eluted with a gradient from DEAE buffer A 
to DEAE Buffer B ( 30 mM Tris, 0.6 M KCI, 10 mM ~-mercaptoethanol,pH 7). 
Fractions were collected. These fractions were also assayed for PBGS activity and 
fractions of high activity were pooled. These pooled fractions were concentrated down to 
a 4 mL sample with Centricon centrifugal concentrators. This sample was then loaded on 
a HiPrep 26/60 Sephacryl S-300 size exclusion column from Ambersham-Pharmacia. 
The column was eluted with S-300 buffer ( 30 mM Tris, 30 mM KCL, 10 mM ~­
mercaptoethanol, pH 7). Fractions were collected and both activity assays and Bradford 
assays were run. The high specific activity showed successful purification. However, 
two activity peaks were observed and thus pooled separately. These two peaks might 
represent different oligomeric states, however no further tests were done to support this. 
Assays 
To determine enzymatic activity, five minute PBGS activity assays were run with 
all mutants and the wild type lO . These assays were run in 0.1 M BTP pH 8.5 buffer in the 
presence of30 mM KCl. These assays were carried out with and without the reducing 
agent, ~-mercaptoethanol. Blanks were used as controls for all assays. The assays were 
then developed with Ehrlich's reagent and absorbance was taken at 555 nm. 
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For all samples Bradford assays were completed to determine total protein 
concentrations. Coomassie Protein Reagent (Pierce Chemical) was reacted with sample 
for 10 minutes then absorbance at 595 nm was taken and compared with a BSA standard 
curve to determine the protein content of each sample. 
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CONCLUSIONS 
The lack of stimulation of C103D by the reducing agent and the maintenance of 
relatively high specific activity suggests that this cysteine participates in a disulfide bond. 
The loss of high specific activity in the C265V mutant obscures whatever the results 
might have been and thus we can draw no conclusions to whether this cysteine 
participates in a disulfide bond. However, the general lowering of specific activity 
suggests that this cysteine residue is otherwise important to the enzymes activity. The 
mutant C309A is still substantially stimulated by the reducing agent but not as stimulated 
as the wild type PBGS. This makes it difficult to draw any type of conclusions on the 
potential participation of this cysteine residue in a disulfide bond. 
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Scheme 1. Balanced reaction catalyzed by PBGS. The conversion of two molecules of 
8-aminolevulinic acid to one molecule of porphobilinogen and two molecules of water. 
The P-site substrate molecule, and what it contributes to the porphobilinogen, is in bold. 
The A-site substrate molecule, and what it contributes to the porphobilinogen, is not in 
bold6. 
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HemeFactor F430 
Figure 2. Structures of some important porphobilinogen derivatives. Clockwise from 
top left is cWorophyll-a, siroheme, vitamin B12, heme, and cofactof F430 11 . 
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Scheme 3. Mechanism proposed for porphobilinogen synthesis proposed by Jordan et. 
al. Both substrate molecules are bound to enzyme through Schiff bases and C-C bond is 
the first one formed II . 
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Scheme 4. Alternate mechanism proposed for porphobilinogen synthesis. Only one of 
the substrate molecules are bound to enzyme through a Schiff base and the C-N bond is 
the first one formed II. 
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Scheme 5. Alternate mechanism proposed for porphobilinogen synthesis. Only one of 
the substrate molecules are bound to enzyme through Schiff bases and the C-C bond is 
the first one formed 11. 
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Figure 6. Inhibitors of PBGS used for inhibition studies to determine the mechanism of 
PBGS. Clockwise from top left the molecules are: a.) 4,7-dioxosebacic acid; b.) 4­
oxosebacic acid; c.) 5-fluorolevulinic acid; 6.) levulinic acid3,6. 
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Figure 7. Homology model of two different zinc binding sites (ZnA and ZnB) in the 
active site of the human PBGS monomers. 
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Figure 8. Two models for Pb(II) interaction with human PBGS. A.) models the 
possibility that Pb(II) is bound to the PbB site (analogous to ZnB site). B.) models the 
possibility that Pb(II) is bound to the hybrid site PbAB (analogous to a hybrid of the ZnA 
and ZnB sites) 5. 
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Figure 9. A model for human PBGS based on the crystal structure of yeast PBGS: 
A.) depicts the dimer in the "69" confirmation and B.) depicts the octamer8. 
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Figure 10. Alignment of amino acid residues considered to be within 8 A of the active site by the human PBGS (PDB code IESI). 
Residues are numbered with respect to the human PBGS sequence. Yellow cysteine residues are ligands to active site zinc. Red 
aspartate residues form putative metal binding sites that do not use active site zinc. Turquoise lysine residues and light blue arginine 
residues cosegregate with the absence and presence of active site zinc respectively. Also, species names in dark blue have sequences 
that indicate a allosteric magnesium binding site4. 
t.;.l 
VI 
36 
Figure 11. Structure ofPBGS monomers from X-ray structures ofE. coli PBGS. The 
active site is located in the center of the a~ barrel. The N-terminal arm is also shown!!. 
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Figure 12. Graphical representation of physiologically relevant interconversion of 
hexameric and octameric PBGS in an allosteric magnesium containing species .The 
hexamer can dissociate into detached dimers in a protein concentration-dependent 
fashion. The detached dimer and hugging dimer are in equilibrium. The hugging dimers 
can form the octamer, also in a protein concentration-dependent way. Allosteric 
magnesium stabilizes the hugging dimer and/or octamer structure2. 
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o Alloster-ic 
Figure 13. Novel classification scheme for PBGS enzymes. The leftmost square 
represents the classification on active site metals. The middle square represents the 
classification based on allosteric site metals. The rightmost square is the munerical 
breakdown of known PBGS sequences into the four groups created by overlaying the two 
classifications3. 
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Figure 14. A stereo diagram of E. coli PBGS active site. Shows highlighted cysteine 
residues complexing a Zn2+. Also, a water molecule and an inhibitor molecule are shown 
over the Zn2+ 4 
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Figure 15. A stereo diagram of the allosteric magnesium binding site ofE. coli PBGS. 
Spheres representing water molecules form an extended ligation network around a central 
R. sphaeroides: TDPSLKTELCEEAWN~NLANRAlRAlKAAVPELAVMTDVALDPYNANGHDGLVRDGI87 IL
146
 
R.capsulatus: 87 TDP~~KTE;CE;~W;P~;;NR~I~K;AVPE~A;MTD;ALDPYNANGHDGLVRDGI 146
lL
R. sphaeroides: 147 NDETVEALVRVmLAQAEAGADILGPSDMMDGRIGAMRTALEAAGHKDVAILSYSAKYASA 206
 
+ - + + - + + +
 
R.capsulatus: 147 NDETTEALVKMALAQAAAGADILGPSDMMDGRVGAIRQAMEAAGHKDIAILSYAAKYASA 206
 
R. sphaeroides: 207 FYGPFRDAVGASGALKGDKKTYQMDPGNSDEALRLIERDLREGADMVMVKPGMPYLDI!R 266
 
R.capsulatus: 207 FYGPFRDAVGAS~ALKGDKKTYQM~P~NS~EALR~~~RD;~EGADMVMVKPGMPYLDI 266
!R
R. sphaeroides: 267 RVKDAFGVPTYAYQVSGEYAMIRGAADRGWIKGEAAMMESLL!FKRAG!DGILTYFAPEA 326
 
R.capsulatus: 267 ;VKDAFG~PTYAYQVSGEYAM~~~~;~GW~~~;~~ESL~F;RAGIDG~LTYFA 326
P~
Figure 16. Alignment of R. capsulatus 1 and R. spaeroides(from http://www.ncbi.nlm.nih.govIBLASTL). Conservative amino acid 
residue changes are denoted by a '+' and nonconservative amino acid residue changes are denoted by a '-'. Cysteine residues near the 
active site are shown with black back grounds, and the active site cysteine residues that are present only in R. sphaeroides are marked 
with an '*'. 
-+:­
o 
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Sample SA w/o p­
mercaptoethanol 
SA wI p­
mercaptoethanol 
Average 
% 
Increase 
in SA 
Highest 
0,,10 
Increase 
in SA 
Lowest 
0,,10 
Increase 
in SA 
CI03D 1281.6 1539.5 20.1 33.6 -3.3 
C265V 455.3 554.7 21.8 33.7 5.3 
C309A 549.3 1053.5 91.8 145.3 64.6 
Wild 
Type 
443.9 1191.6 168.4 248.6 114.4 
Figure 17. Table of the averages of the specific enzymatic activity of all three mutants 
and wild type, in the presence and absence of p-mercaptoethanol. Al.so, give average, 
highest and lowest percent increase in specific activity by p-mecaptoethanol 
--
-- - ----
---
-- --- --
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Stimulation of PBGS Specific Activity
 
by ~-mercaptoethanol
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C103D	 C265V C309A Wild Type 
Sample 
Figure 18. Graph of the the average ( blue diamond), highest (pink square), and lowest 
(yellow triangle) percent decreases in specific activity in each mutant and wild type when 
activity assays were perfonned with out ~-mercaptoethanol 
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Mutant C103D: 357 ggcctggaaccccgacaacctcgccaaccgg 387 
1111111111111 1I11II1111111111 
R.sphaeroides: 617 ggcctggaacccctgcaacctcgccaaccgg 647 
Figure 19. Excerpt from sequence alignment between mutant 
C103D against R. sphaeroides (using 
http://www.ncbi.nlm.nih.gov/BLASTI) done wi th T7 promoter primer 
(reads 5' to 3'). Mismatches are indicated by the lack of a 
vertical bar between the two bases. 
44 
Mutant C256V: 227 gcgtccttcacccgccggacgatgtcgagataggg 262 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
R.sphaeroides:116l gcgtccttcacccgccggcagatgtcgagataggg 1077 
Figure 20. Excerpt from sequence alignment between mutant 
C256V against R. sphaeroides (using 
http://www.ncbi.nlm.nih.gov/BLAST/) from terminator primer (reads 3' 
to 5'). Mismatches are indicated by the lack of a vertical 
bar between the two bases. 
